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Edited by Varda RotterAbstract Acidic extracellular pH (pHe) is a typical attribute of
a tumor microenviroment, which has an impact on cancer
development and treatment outcome. It was believed to result
from an accumulation of lactic acid excessively produced by
glycolysis. However, metabolic proﬁles of glycolysis-impaired
tumors have revealed that CO2 is a signiﬁcant source of acidity,
thereby indicating a contribution of carbonic anhydrase (CA).
The tumor-associated CA IX isoform is the best candidate,
because its extracellular enzyme domain is highly active,
expression is induced by hypoxia and correlates with poor
prognosis. This study provides the ﬁrst evidence for the role of
CA IX in the control of pHe. We show that CA IX can acidify
the pH of the culture medium in hypoxia but not in normoxia.
This acidiﬁcation can be perturbed by deletion of the enzyme
active site and inhibited by CA IX-selective sulfonamides, which
bind only to hypoxic cells containing CA IX. Our ﬁndings
suggest that hypoxia regulates both expression and activity of
CA IX in order to enhance the extracellular acidiﬁcation, which
may have important implications for tumor progression.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Acidic extracellular pH (pHe) has been associated with tu-
mor progression via multiple eﬀects including upregulation of
angiogenic factors and proteases, increased invasion, and im-
paired immune functions [1–5]. In addition, it can inﬂuence the
uptake of anticancer drugs and modulate the response of tu-* Corresponding author. Fax: +421-2-5477-4284.
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tumor microenvironment was generally attributed to the ac-
cumulation of lactic acid excessively produced by glycolysis
and poorly removed by inadequate tumor vasculature. A high
rate of glycolysis is especially important for the hypoxic cells
that largely depend on anaerobic metabolism for the energy
generation. However, experiments with glycolysis-deﬁcient
cells indicate that production of lactic acid is not the only
mechanism leading to tumor acidity. The deﬁcient cells pro-
duce only diminished amounts of lactic acid, but form acidic
tumors in vivo [7,8]. A comparison of the metabolic proﬁles of
the glycolysis-impaired and parental cells revealed that CO2, in
addition to lactic acid, is a signiﬁcant source of acidity in tu-
mors [9]. These data strongly imply possible contribution of
carbonic anhydrase (CA), a zinc metalloenzyme catalyzing the
reversible conversion of CO2 to bicarbonate and a proton.
Mammalian CA exists in at least 15 isoforms diﬀering in
molecular properties, subcellular localization, tissue distribu-
tion, and kinetic properties. The active CA isoenzymes are
fundamental for various physiological processes that involve
ion exchange and pH balance. They can be eﬃciently inhibited
by sulfonamides, which are clinically exploited for the treat-
ment of disorders associated with abnormal CA activity [10].
The CA IX isoform appears to be the best candidate for a
role in acidiﬁcation of the tumor microenvironment. First,
CA IX is an integral plasma membrane protein with an ex-
tracellularly exposed enzyme active site [11,12]. Second, CA
IX has a very high catalytic activity with the highest proton
transfer rate among the known CAs [13]. Third, CA IX is
present in few normal tissues, but its ectopic expression is
strongly associated with many frequently occurring tumors
[14]. Finally, CA IX level dramatically increases in response
to hypoxia via a direct transcriptional activation of CA9 gene
by hypoxia inducible factor-1 (HIF-1) [15] and its expression
in tumors is a sign of poor prognosis [16]. Taken together,
CA IX has all necessary predispositions needed to act in the
control of tumor pH.
To obtain support for this concept, we focused on the ca-
pacity of CA IX to acidify extracellular pH (pHe) in culture.
Using MDCK epithelial cells that constitutively express a hu-
man CA IX protein, we proved that CA IX is able to decrease
the pHe of the culture medium in response to low oxygen,
suggesting that hypoxia stimulates its enzymatic activity.lished by Elsevier B.V. All rights reserved.
Fig. 1. CA IX-mediated acidiﬁcation of the extracellular pH in hypoxia. (A) CA IX-transfected MDCK cells and mock-transfected controls were
either maintained in normoxia (N, 21% O2) or exposed to hypoxia (H, 2% O2) for 48 h and analyzed by immunoblotting using M75 MAb. (B)
Immunoﬂuorescence analysis of the transfected MDCK cells. Values of pHe (C) and lactate concentrations (D) in the cells grown in constant medium
volumes were obtained in ﬁve independent experiments with three diﬀerent clones of the transfectants and three parallel dishes for each clone. Results
are illustrated on the histogram showing the mean values and standard deviations.
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perturbed the extracellular acidiﬁcation exerted by endogenous
CA IX protein produced in hypoxic HeLa cells. In both models,
CA IX-selective sulfonamides reduced the medium acidiﬁcation
and bound only to hypoxic cells containing the wild-type CA
IX. Our results suggest that CA IX can contribute to acidiﬁ-
cation of the hypoxic extracellular milieu, which may have
important implications for the development of cancer.2. Materials and methods
2.1. Cell culture
MDCK,SiHa,HeLa cells and their transfectedderivativeswere grown
in DMEM with 10% FCS and buﬀered with 22.3 mM bicarbonate [17].
Tomaintain the standard conditions, the cells were always plated in 3ml
of culturemediumat adensityof 0.8–1 106 per 6 cmdish 24hbefore the
transfer to hypoxia (2%O2 and5%CO2 balancedwithN2) generated in a
Napco 7000 incubator. Parallel normoxic dishes were incubated in air
with 5% CO2. At the end of each experiment, pH of the culture medium
was immediately measured, the medium was harvested for the determi-
nation of the lactic acid content with the standard assay kit (Sigma), the
cells were counted to ensure that the resulting cultures are comparable
and then processed either for immunoﬂuorescence or extracted for im-
munoprecipitation and/or immunoblotting.
2.2. Sulfonamide synthesis and treatment of cells
CAI#1 sulfonamide [4-(2-aminoethyl)-benzenesulfonamide] was ob-
tained from Sigma–Aldrich. The membrane-impermeable CAI#2
[4-(2,4,6-trimethylpyridinium-N-methylcarboxamido)-benzenesulfona-
mide perchlorate] was prepared by reaction of homosulfanilamide with2,4,6-trimethyl pyrilium perchlorate [18]. The ﬂuorescent CAI#3 sul-
fonamide was obtained from homosulfanilamide and ﬂuorescein iso-
thiocyanate [19]. CAIs showed the following KI values assessed by CO2
hydration methods using the puriﬁed CA domain of CA IX: CAI#1 36
nM, CAI#2 38 nMandCAI#3 24 nM. The sulfonamides were dissolved
in PBS with 20% DMSO at 100 mM concentration and diluted in a
culture medium to a required ﬁnal concentration just before their ad-
dition to cells. The cells were incubated for 48 h in hypoxia and nor-
moxia, respectively, pH of the culture medium was measured and the
binding of the FITC-labeled CAI#3 to living cells, washed three times
with PBS, was viewed by a Nikon E400 epiﬂuorescence microscope.
2.3. Cloning of CA IX mutants and transfection
Cloning of CA IX deletion mutants lacking either the N-terminal
PG domain or the central CA domain was performed as described
[20]. MDCK and HeLa cell lines constitutively expressing CA IX
protein or its mutants were obtained by cotransfection of re-
combinant plasmids pSG5C-CA IX, pSG5C-DCA and pSG5C-DPG
with pSV2neo plasmid in a 10:1 ratio using a GenePorter II trans-
fection kit from Gene Therapy Systems. The transfected cells were
subjected to selection in 500–1000 lg/ml G418, cloned, tested for CA
IX and expanded. At least three clonal cell lines expressing each CA
IX form were analyzed to eliminate the eﬀect of clonal variation. The
cells cotransfected with empty pSG5C and pSV2 neo were used as
negative controls.
2.4. Indirect immunoﬂuorescence and immunoblotting
Cells grown on glass coverslips were ﬁxed in ice-cold methanol at
)20 C for 5 min and stained with CA IX-speciﬁc monoclonal anti-
body (MAb) M75 directed to the PG domain or V/10 directed to the
CA domain followed by incubation with FITC-labeled secondary an-
tibodies [20,21]. For immunoblotting, cells were rinsed with PBS and
extracted in RIPA buﬀer for 30 min on ice. Protein concentrations
were quantiﬁed using the BCA kit (Pierce). The proteins (50 lg/lane)
Fig. 2. Sulfonamide inhibition and binding to hypoxic MDCK-CA IX cells. (A) Chemical structures of the CA IX-selective inhibitors used in this
study: CAI#1 [4-(2-aminoethyl)-benzenesulfonamide], CAI# 2 [4-(2,4,6-trimethylpyridinium-N-methylcarboxamido)-benzenesulfonamide perchlo-
rate], CAI#3 [ﬂuorescein-thioureido-homosulfanilamide]. (B) The sulfonamides were added to MDCK-CA IX cells just before their transfer to
hypoxia and pHe was measured 48 h later. At least three independent experiments with three parallel dishes per sample were performed for each
inhibitor. Data are expressed as diﬀerences between the pH values (DpH) measured in the untreated versus treated cells and include the standard
deviations. (C) Fluorescence analysis of the transfected MDCK cells plated on the glass coverslips. The cells were treated with the FITC-labeled
CAI#3 throughout the 48 h incubation in normoxia and hypoxia, respectively.
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conditions, respectively, transferred to PVDF membrane and CA IX
was detected with the speciﬁc MAbs as described [21].
2.5. Cell biotinylation and immunoprecipitation
Cells were washed with ice-cold buﬀer A (20 mM sodium hydrogen
carbonate, 0.15 M NaCl, pH 8.0), incubated for 60 min at 4 C with
buﬀer A containing 1 mg of NHS-LC-Biotin (Pierce), then washed 5
times with buﬀer A and extracted in RIPA as described above. MAb V/
10 in 1 ml of hybridoma medium was bound to 25 ll of 50% sus-
pension of Protein-A Sepharose (Pharmacia) for 2 h at RT. Biotiny-
lated extract (200 ll) was pre-cleared with 20 ll of 50% suspension of
Protein-A Sepharose and then added to the bound MAb. Immuno-
complexes collected on the Protein-A Sepharose were separated by
SDS–PAGE, transferred to a PVDF membrane and revealed with
peroxidase-conjugated streptavidin (1/1000, Pierce) followed by en-
hanced chemoluminescence.3. Results and discussion
3.1. Ectopic expression of CA IX leads to increased acidiﬁcation
of pHe in hypoxia
Expression of CA IX in tumor cells is induced by hypoxia
simultaneously with various components of anaerobic metab-
olism and acid extrusion pathways. This could complicate thedetermination of the contribution of CA IX to the overall
change in pHe. Therefore, we used MDCK immortalized ca-
nine kidney epithelial cells that do not express endogenous CA
IX, but were stably transfected to express the human CA IX
protein in a constitutive manner. Levels of CA IX in MDCK-
CA IX transfectants were comparable between the hypoxic
cells maintained for 48 h in 2% O2 and the normoxic cells
incubated in 21% O2 (Fig. 1A). CA IX was predominantly
localized at the cell surface (Fig. 1B), although the membrane
staining in hypoxic cells was less pronounced due to a hypoxia-
induced perturbation of intercellular contacts [17]. Hypoxic
incubation led to expected extracellular acidiﬁcation in the CA
IX-positive as well as CA IX negative cell cultures when
compared to their normoxic counterparts (Fig. 1C). However,
upon mutual comparison of the hypoxic cells it was evident
that pHe was signiﬁcantly decreased in the cells containing CA
IX. Taking into account a steady, hypoxia-independent level
of CA IX in MDCK-CA IX cells, this ﬁnding indicated that
hypoxia activated the catalytic performance of CA IX, which
resulted in enhanced pHe acidiﬁcation.
To exclude the possibility that hypoxia-induced acidiﬁcation
was caused by an increased production of lactic acid, we de-
termined corresponding lactate concentrations in the media
Fig. 3. Expression and acidiﬁcation capability of the CA IX deletion mutants. (A) Schematic drawing of the domain composition of the wild-type
(wt) CA IX with the amino acid positions indicating the extent of the deletions in the N-terminal PG domain (DPG) and the central CA domain
(DCA): SP, signal peptide; PG, proteoglycan-like region; CA, carbonic anhydrase domain; TM, transmembrane anchor; IC, intracytoplasmic tail. (B)
Immunoﬂuorescence analysis with M75 and V/10 MAbs speciﬁc for diﬀerent extracellular parts of CA IX. (C) Immunoblotting of DCA and DPG
proteins. The proteins were analyzed under both reducing (2ME+) and non-reducing (2ME)) conditions for their Mw and their capacity to form
oligomers. (D) Extracellular pH and lactate in the transfected MDCK cells. At least three independent experiments were performed using three clonal
cell lines for each transfected variant with at least three parallel dishes. Data are expressed as mean diﬀerences in the pH values (DpH) and in the
lactate concentrations (Dmg/ml), respectively.
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(Fig. 1D). In accord with the literature, production of lactic
acid was signiﬁcantly higher in the cells maintained in hypoxia
than in the normoxic cells. However, there were practically no
diﬀerences between the lactate production in cultures of CA
IX-positive and CA IX-negative cells, suggesting that the ex-
cessive pHe decrease observed in hypoxia could be explained
by the activation of CA IX.
3.2. Sulfonamides inhibit CA IX-mediated acidiﬁcation of pHe
and bind to hypoxic MDCK-CA IX cells
Sulfonamides eﬃciently inhibit CAs by a well-understood
mechanism [10]. Despite a principally non-speciﬁc action
against diﬀerent CA isoenzymes, sulfonamide structure and
properties can be modiﬁed to introduce certain preferences for
the particular isoforms. We tested three CA IX-selective in-
hibitors (CAI, Fig. 2A). CAI#1 is a strong inhibitor of CA IX,
whereas it is less eﬃcient against the widely distributed cyto-
plasmic CA II and the plasma membrane-anchored CA IV [22],
CAI#2 is practically membrane-impermeable [18] and CAI#3
has a big moiety favoring its interaction with the CA IX active
site, which is assumed to form a larger cavity than in CA II [23].All three sulfonamides were able to reduce the extracellular
acidiﬁcation of MDCK-CA IX cells in hypoxia and their eﬀect
on the normoxic pHe was negligible (Fig. 2B). Moreover,
FITC-labeled CAI#3 was detected only in hypoxicMDCK-CA
IX cells, but was absent from their normoxic counterparts and
from the mock-transfected controls (Fig. 2C). Cytoplasmic
accumulation of CAI#3 was possibly related to the hypoxia-
induced internalization of CA IX described earlier [17]. Lack of
the ﬂuorescence signal in the CA IX-negative MDCK cells
conﬁrmed the selectivity of the inhibitor, which did not bind to
other potentially present CA isoforms and indicated that only
the hypoxic MDCK-CA IX cells contain the catalytically active
CA IX with the enzyme center accessible to an inhibitor. The
latter claim is supported by the generally accepted fact that the
reaction between CA and an inhibitor occurs principally via a
coordination of the ionized inhibitor to the zinc ion through the
network of hydrogen bonds with amino acid residues of the
active site, which eﬀectively means that the inhibitor can eﬃ-
ciently bind only to active CA isoforms [10]. It cannot be ex-
cluded that hypoxia inﬂuences the conformation and hence the
accessibility of the active site of CA IX, but this assumption
warrants further studies.
Fig. 4. Treatment of the tumor cells by CAI#3 sulfonamide. (A) HeLa and SiHa cervical carcinoma cells were incubated for 48 h in normoxia and
hypoxia, respectively, either in the absence or in the presence of 1 mM CAI#3 sulfonamide. Mean diﬀerences in the pH values determined in the
treated versus control dishes are shown on the histogram with indicated standard deviations. The experiment was repeated three times using at least
three parallel dishes for each sample. (B) HeLa and SiHa cells plated on the coverslips were treated with FITC-labeled CAI#3 sulfonamide during
48 h incubation in normoxia and hypoxia, washed with PBS and inspected under the ﬂuorescence microscope. (C) Immunoblotting analysis of CA IX
expression in the normoxic and hypoxic carcinoma cells with M75 MAb.
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extracellular acidiﬁcation in hypoxia
In addition to the enzyme domain (CA), the extracellular
part of CA IX contains an N-terminal proteoglycan-related
region (PG) that is absent from the other CAs and seems
implicated in cell adhesion [24]. To examine involvement of
these domains in the pHe control, we produced deletion
variants of CA IX, in which we removed either the PG
region (DPG) or a large portion of the CA domain (DCA),
Fig. 3A. Immunoﬂuorescence analysis using two MAbs,
namely PG-speciﬁc M75 for DCA and CA-speciﬁc V/10 for
DPG, has shown that both deleted proteins were transported
to the plasma membrane (Fig. 3B). The mutants were ex-
pressed at levels comparable with the wild-type CA IX
(Fig. 3C). Interestingly, DCA was unable to form oligomers
possibly due to the absence of two out of four cysteines
(C174 and C336) required for the proper S-S bonding. As
judged from the molecular weights, DPG mutant appeared
to assemble into dimeric and tetrameric complexes, rather
than into trimers. Elimination of a large part of the CA
domain perturbed the acidiﬁcation capacity of CA IX,
whereas removal of the PG region had no such eﬀect(Fig. 3D). This diﬀerential behavior could be reasonably
attributed to the absence versus presence of the catalytic
activity of CA IX, because the cells expressing these variants
produced similar levels of lactic acid (Fig. 3D). It also in-
dicates that the CA domain is both necessary and suﬃcient
for the enzyme activity and that PG and CA portions of CA
IX molecule can be functionally separated, although they
may still cooperate in response to diverse physiological
factors. Based on the knowledge that the extracellular aci-
dosis interferes with the cell adhesion, the enzyme activity
carried out by CA domain might inﬂuence the adhesion-
related properties of PG region and vice versa. Indeed, CA
IX was shown to destabilize E cadherin-mediated intercel-
lular adhesion in transfected MDCK cells, which was par-
ticularly dramatic in the hypoxic monolayer [17] in
conditions accompanied by CA IX-mediated extracellular
acidosis described here.
3.4. FITC-CAI #3 sulfonamide binds to and increases pHe of
the hypoxic tumor cells
To see whether the phenomenon of CA IX-mediated
acidiﬁcation is applicable to tumor cells with endogenous
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the pHe of the cervical carcinoma cells HeLa and SiHa,
respectively. Under hypoxia, tumor cells coordinately express
elevated levels of multiple HIF-1 targets, including CA IX
[25]. In addition, activity of many components of the hyp-
oxic pathway and related pH control mechanisms, such as
ion transport across the plasma membrane, are abnormally
increased in order to maintain the neutral intracellular pH
[1]. This explains the considerably decreased pHe of the
hypoxic versus normoxic HeLa and SiHa cells (Fig. 4A).
The acidosis was partially reduced by CAI#3 inhibitor, in
support of the idea that activation of CA IX is just one of
the many consequences of hypoxia. Moreover, FITC-CAI#3
accumulated in the hypoxic HeLa and SiHa cells that con-
tained elevated levels of CA IX, but not in the normoxic
cells with a diminished CA IX expression (Fig. 4B and C).
As indicated by the ability to bind CAI#3 and mediate its
accumulation in hypoxia, CA IX expressed in the hypoxic
tumor cells was catalytically active. Exclusive binding of the
FITC-conjugated CAI#3 sulfonamide to the hypoxic cells
that express activated CA IX oﬀers an attractive possibilityFig. 5. Ectopic expression of DCA mutant in HeLa cells. (A) Immunoﬂouresc
was performed either with V/10 MAb (to detect endogenous CA IX protein
Immunoblotting analysis of HeLa-DCA cells as well as the mock-transfected
and hypoxia (H), and analyzed under reducing (C) and non-reducing condit
with DCA in comparison to the mock-transfected controls. Data represent me
The experiment was repeated three times with three diﬀerent clones of the tfor the use of similar sulfonamide-based compounds for the
imaging purposes in vivo. Moreover, CA IX-selective sul-
fonamide derivatives may potentially serve as components of
the therapeutic strategies designed to increase pHe in the
tumor microenvironment and thereby reduce the tumor ag-
gressiveness and the drug uptake [1,6,26,27].3.5. Expression of DCA mutant in HeLa cells reduces their pHe
acidiﬁcation in hypoxia
Based on the assumption that the enzyme-dead DCA mutant
could abolish the function of the endogenous CA IX protein,
we generated HeLa-DCA transfectants. These cells contained
DCA but not CA IX under normoxia, expressed both proteins
under hypoxia, and in the non-reducing conditions exhibited
an atypical band presumably corresponding to mixed oligo-
mers composed of both CA IX and DCA (Fig. 5A–C). No
signiﬁcant diﬀerences in pHe were observed between the
normoxic HeLa-mock and HeLa-DCA cells. On the other
hand, HeLa-DCA transfectants treated by hypoxia produced
less acidic medium than the control HeLa-mock cellsence analysis of the mock-transfected and DCA-transfected HeLa cells
) or with M75 MAb (to visualize both CA IX and DCA mutants). (B)
controls using M75 MAb. The cells were maintained in normoxia (N)
ions (D). Values of pHe in the culture media of HeLa cells transfected
an diﬀerences in the pH values and corresponding standard deviations.
ransfected HeLa, each having at least three parallel dishes.
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interfered with the activity of the wild-type protein, and fur-
ther supporting the role of CA IX. Altogether, these data
strongly imply that the acidiﬁcation of the extracellular pH in
the hypoxic tumor cells does involve CA activity and that CA
IX directly participates in this phenomenon.
3.6. How might CA IX contribute to extracellular acidosis?
In the context of the above results that place CA IX among
the direct contributors to the hypoxic microenvironment, it is
tempting to propose possible means of its action. Data ob-
tained from studies with the physiologically relevant CA iso-
forms II and IV indicate that these CAs physically interact
with anion exchangers (AE) to form a metabolon that facili-
tates bicarbonate transport in diﬀerentiated cells [28,29]. It
seems plausible that CA IX could work as an extracellular
component of the similar metabolon in tumor cells. Assembly
and/or activation of such a metabolon would be especially
meaningful in low oxygen conditions, because a highly eﬃcient
transport of bicarbonate is required particularly in the hypoxic
cells for the buﬀering of intracellular pH and biosynthetic re-
actions. According to this model, enhanced conversion of CO2
to bicarbonate by the hypoxia-activated CA IX would be
coupled with the increased production of extracellular protons
contributing to acidosis. Data obtained in this work ﬁt well
with this proposal. Further supportive hints come from the
studies of von Hippel-Lindau tumor suppressor protein
(pVHL), the main negative regulator of HIF-1, which can
downregulate CA IX (obviously as a direct HIF-1 target) and
can also reduce the transport activity of AEs [30,31].
Downstream eﬀects of CA IX can be at least partially antici-
pated on the basis of the known connections between the acidic
pHe and certain features of the tumor phenotype [1–6]. More-
over, as a part of the hypoxic acidiﬁcation machinery, CA IX
might facilitate a nucleolar sequestration of pVHL and activa-
tion of HIF, which is a recently described pH-dependent mech-
anism proposed to serve a protective role in reoxygenated cells
[32]. In such case,HIF-mediated increase in the level and activity
of CA IX resulting in enhanced acidiﬁcation might create a
feedback loop leading to prolonged HIF activation, which is
certainly an attractive possibility requiring experimental proof.
In conclusion, this study provides the ﬁrst direct evidence for
the role of CA IX in acidiﬁcation of extracellular pH. Our
ﬁndings signiﬁcantly improve the view of CA IX as a molecule,
whose expression levels as well as catalytic activity are regu-
lated by oxygen availability, and thus open new possibilities
for its better understanding and clinical exploitation.
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